Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.46 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 12/20 | 0.46 |
| ▸ | MTNR1B | P49286 | 12/20 | 0.46 |
| ▸ | ACACB | O00763 | 1/20 | 0.38 |
| ▸ | ACACA | Q13085 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | GFPT1 | Q06210 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18364241 | 1.00 | HCAR2 (0.46) | HCAR2KEAP1NFE2L2MTNR1AMTNR1B | |
| SCHEMBL18364237 | 1.00 | HCAR2 (0.46) | HCAR2KEAP1NFE2L2MTNR1AMTNR1B | |
| SCHEMBL18412200 | 0.94 | MTNR1A (0.50) | HCAR2KEAP1NFE2L2MTNR1AMTNR1B | |
| SCHEMBL18412225 | 0.94 | MTNR1A (0.50) | HCAR2KEAP1NFE2L2MTNR1AMTNR1B | |
| SCHEMBL18364293 | 0.88 | HCAR2 (0.48) | HCAR2MTNR1AMTNR1BACACBACACA | |
| SCHEMBL18364201 | 0.88 | HCAR2 (0.48) | HCAR2MTNR1AMTNR1BACACBACACA | |
| SCHEMBL18406345 | 0.88 | HCAR2 (0.48) | HCAR2MTNR1AMTNR1BACACBACACA | |
| SCHEMBL18364749 | 0.86 | MTNR1A (0.44) | HCAR2MTNR1AMTNR1BACACBACACA | |
| SCHEMBL18406367 | 0.86 | HCAR2 (0.47) | HCAR2MTNR1AMTNR1BACACBACACA | |
| SCHEMBL18364764 | 0.86 | MTNR1A (0.44) | HCAR2MTNR1AMTNR1BACACBACACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170022149-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | Nguyen, Mark Quang (US) | 2017-01-26 | — | — | US | disclosed |
| US-20170022149-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | Nguyen, Mark Quang (US) | 2017-01-26 | — | — | US | disclosed |
| US-20170008835-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | Nguyen, Mark Quang (US) | 2017-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170022149-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | FH, FPGS, APC | HCAR2 290/4885KEAP1 468/4885NFE2L2 399/4885 |
| US-20170008835-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | FH, FPGS, APC | HCAR2 290/4885KEAP1 468/4885NFE2L2 399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.